OS Therapies stockholders back director slate, pay plan changes at 2026 annual meeting
Shareholders holding a majority of votes present approved all six director nominees, an updated incentive compensation plan, and the auditor's reappointment at the September 9 meeting.
OS Therapies Incorporated held its 2026 annual meeting of stockholders on September 9, 2026, according to an 8-K filed with the SEC. The Company held the Annual Meeting on September 9, 2026.1
Voting was based on the presence in person or by proxy of holders of record of 26,059,902 of the 46,205,601 shares of the Company's common stock entitled to vote1.
Stockholders elected six director nominees to serve until the 2027 annual meeting: Paul A. Romness, John Ciccio, Craig Eagle, Avril McKean Dieser, Olivier R. Jarry, and Theodore F. Search. Each nominee received between roughly 7.1 million and 7.3 million "for" votes, with withheld votes ranging from about 67,600 to nearly 294,000, and broker non-votes of 18,655,389 for every nominee.1
Shareholders also approved amendments to the company's existing equity compensation plan. On September 9, 2026, the stockholders of OS Therapies Incorporated approved and adopted the amendment and restatement of the Company's 2023 Incentive Compensation Plan, as amended, at its 2026 annual meeting of stockholders.1 That vote tallied 4,515,930 shares for, 885,667 against, 2,002,913 abstentions, and 18,655,392 broker non-votes1.
Finally, stockholders ratified MaloneBailey, LLP to continue as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, with 25,689,179 votes for, 340,644 against, 30,079 abstentions, and no broker non-votes recorded1.
The filing was signed by Paul A. Romness, MPH, President and Chief Executive Officer of OS Therapies Incorporated.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.